



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated: 13-10-2008

Mr. Munir Ahmed,
Director (Admn.),
IPO-Pakistan,
Islamabad.

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 13-10-2008 TO BE PUBLISHED 14-10-2008 IN
THE GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 13-10-2008

To,

Mr. Manzoor Ahmed
Section Officer
Cabinet Secretariat
Cabinet Division
Government of Pakistan
Islamabad

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 13-9-2008 TO BE PUBLISHED 14-10-2008 IN THE
GAZETTE OF PAKISTAN PART-V.**

Reference to Cabinet Secretariats letter No. 18/IPO/2008/RA-IV, dated 23rd April 2008. A manuscript copy of the weekly notification regarding application filed, application accepted and sealing fee due etc., is enclosed herewith for onward transmission to the Printing Corporation of Pakistan Press for publication in the next issue of the Gazette of Pakistan Part-V.

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

1074/2008	<u>08-9-2008</u> Douglas C. Comrie, USA	“Carbon dioxide sequestration materials and processes”
1075/2008	<u>09-9-2008</u> Glaxo Group Limited, United Kingdom (Priority 11-9-07 GB)	“Compounds which inhibit the glycine transporter and uses thereof in medicine”
1076/2008	<u>10-9-2008</u> AstraZeneca AB, Sweden (Priority 11-9-07 USA)	“New compounds 966”
1077/2008	Eisai R and D Management Co., Ltd. Japan (Priority 28-7-06 Japan) Divisional	“Prodrug of cinnamide compounds”
1078/008	Boehringer Ingelheim International GmbH, Germany (Priority 12-9-07 USA)	“Treatment of vasomotor symptoms”
1079/2008	Wyeth, USA (Priority 12-9-07 USA)	“Azacyclyl isoquinolinone and isoindolinone derivatives as histamine-3 antagonists”
1080/2008	<u>11-9-2008</u> J. M. Huber Corporation, USA	“High-cleaning silica materials made via product morphology control under high shear conditions”
1081/2008	J. M. Huber Corporation, USA	“High-cleaning low abrasion, high brighthees silica materials for dentifrices,”
1082/2008	Renovo Limited, GB	Medicaments and proteins”
1083/008	Muhammad Zahid Karachi Pakistan	“Ball screw lifting mechanisim with stroke multiplier for work platform as ground support

		equipment for air craft maintenance”
1084/2008	Glaxo Group Limited, United Kingdom (priority 13-9-07 GB)	“Novel Pharmaceutical”
1085/2008	Palm-Organies Global Ltd. Islands (Priority 24-9-07 GB)	“Growing medium system”
1086/2008	Wyeth, USA (Priority 12-9-2007 USA)	“Isoquinolinyll and isoindolinyll derivatives as histamine-3 antagonists”
1087/2008	Peptcell Limited, United Kingdom (Priority 13-9-07 UK)	“Peptide sequences and compositions”
1088/2008	Syngenta Participations AG, Switzerland (Priority 18-9-2007 GB)	“Chemical compounds”
	<u>12-9-2008</u>	
1089/2008	Pfizer Limited, United Kingdom (Priority 14-9-07 USA)	“Novel compounds active as muscarinic receptor antagonists”
1090/2008	Janssen Pharmaceutica N.V., Belgium (Priority 14-9-07 USA)	“Theino-and furo-pyrimidine modulatoros of the histamine H4 receptor”
1091/2008	LES Laboratoires Servier France (Priority 21-9-07 France)	“New addition salts of angiotensin-converting enzyme inhibitors with no donor acids, a process for their preparation and pharmaceutical compositions containing them”
	<u>13-9-2008</u>	
1092/2008	M/s. Kamal Traders PCSIR, Karachi, Pakistan	“A process for the preparation of farihas lubna toner/lotion”
1093/2008	Barrick Gold Corporation Canada (Priority 18-9-07 USA)	“A process for reduced alkali consumption in the recovery of silver”
1094/2008	Barrick Gold Corporation Canada (Priority 18-9-07 USA)	“A process for recovering precisous metals form refractory ores”

1095/2008

Barrick Gold Corporation
Canada
(Priority 17-9-07 USA)

“Method to improve recovery of gold from
double refractory gold ores”

††††††††††††††††

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.


Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

495/2003 Merck & Co. Inc., "11-Beta-hydroxysteriod dehydrogenase compound"
USA.

(CO7D, 249/08)

139796

Compound having Formula 1




is selective inhibitor of the 11 β -HSD1 enzyme. The compound is useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, syndrome X, and other symptoms associated with NIDDM.

1099/2003 Syngenta
Participations AG., "Avermectin B1 and avermectin B1 monosaccharide
Switzerland. compound having an alkoxyethyl substituent in the
4''-OR 4''-position"

(AO1K, 43/90 A61K, 31/7048)

A compound of the
Formula



wherein

n is 0 or 1; A-B is -CH=CH- or -CH₂-CH₂-;

R₁ is C₁-C₁₂-alkyl, C₃-C₈-cycloalkyl or C₂-C₁₂-alkenyl;

R₂ is for example C₁-C₁₂-alkyl, C₂-C₁₂-alkenyl or C₂-C₁₂-alkynyl; which are optionally substituted with one to five substituents selected from the group consisting of OH, halogen,

CN, -N₃, -NO₂, C₃-C₈-Cycloalkyl, norbornylenyl-, C₃-

C₈-Cycloalkenyl; C₃-C₈-halocycloalkyl,

C₁-C₁₂-alkoxy, C₁-C₆-alkoxy-C₁-C₆-alkoxy, C₃-C₈-

cycloalkoxy, C₁-C₁₂-haloalkoxy, C₁-C₁₂-alkylthio, C₃-

C₈-cycloalkylthio, C₁-C₁₂-haloalkylthio, C₁-C₁₂-

alkylsulfinyl, C₃-C₈-cycloalkylsulfinyl,

C₁-C₁₂-haloalkylsulfinyl, C₃-C₈-halocycloalkylsulfinyl,

C₁-C₁₂-alkylsulfonyl, C₃-C₈-cyclo-

alkylsulfonyl, C₁-C₁₂-haloalkylsulfonyl, 3-C₈-

halocycloalkylsulfonyl, -NR₄R₆, -X-C(=Y)-R₄,

-X-C(=Y)-Z-R₄, -P(=O) (OC₁-C₆-alkyl)₂, aryl,

heterocyclyl, aryloxy, arylthio and heterocyclyl-oxy;

R₃ is for example H, C₁-C₁₂-alkyl or C₁-C₁₂-alkyl

which is optionally substituted and, where applicable,

to E/Z isomer, mixture of E/Z isomer and/or

tautomer, in each

case in free form;

and using the compound and its tautomer; pesticides

whose active compound is selected from these

compound and their tautomer; compound and


composition, and the use of these compound and

composition.

579/2006 Sanofi-Aventis Deutschland GmbH, Germany “Substituted 1,4-benzothiazepine 1,1-dioxide compound” (A61K, 31/554)

139798

The invention relates to the compound of the Formula A.




A

The compound is suitable, for example, as a hypolipidemic.

1140/2006 Merck & Co. Inc., USA. “A pharmaceutically acceptable salt of 11-Beta-hydroxysteroid dehydrogenase compound” (CO7D, 249/08)

139799

Compound having Formula 1 including pharmaceutically acceptable salt, hydrate and solvate thereof:



I

is selective inhibitors of the 11 β -HSD1 enzyme. The compound is useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, syndrome X, and other symptoms associated with NIDDM.

SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139404	Jassen Pharmaceutica N.V., Belgium	391/1997
139405	Jassen Pharmaceutica N.V., Belgium	392/1997
139406	Jassen Pharmaceutica N.V., Belgium	393/1997
139407	Bristol-Myers Squibb Company, USA	127/1998
139408	Jassen Pharmaceutica N.V., Belgium	712/1998
139409	Pfizer Inc., USA.	1039/1998
139410	Wyeth Holdings Corporation, USA.	821/1999
139411	Bristol-Myers Squibb Company, USA	1041/1999
139412	Unilever Plc, England	80/2000
139413	American Cyanamid Company, USA.	119/2000
139414	SmithKline Beecham p.l.c., England	342/2000
139415	Bristol-Myers Squibb Company, USA	1023/2000
139416	Glaxo Group Limited, Great Britain	1098/2000
139417	Bristol-Myers Squibb Company,	1164/2000

	USA	
139418	Bristol-Myers Squibb Company, USA	170/2002
139419	Wyeth, USA.	177/2002
139420	E.I. Du Pont De Nemours and Company, USA	703/2002
139421	Warner-Lambert Company, USA	1016/2002
139422	Bristol-Myers Squibb Company, USA	431/2003
139423	Unilever Plc., UK.	1120/2005
139424	Bristol-Myers Squibb Company, USA	1148/2006
139425	Bristol-Myers Squibb Company, USA	1332/2006

(MRS. YASMEEN ABBASI)
CONTROLLER OF PATENTS
Tel: 9215488